In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Commentary|Videos|June 20, 2025
Evolving Paradigms in Relapsed DLBCL: Part 2
Author(s)Manali Kamdar, MD
Manali Kamdar, MD, discusses evolving treatment paradigms in diffuse large B-cell lymphoma.
Advertisement
Manali Kamdar, MD, discusses evolving treatment paradigms in diffuse large B-cell lymphoma.
Advertisement
Related to this article
A rituximab biosimilar has been approved by the FDA.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5